Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients
Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Intervention: Higher-dose inhaled corticosteroids (Drug); Low-dose fixed dose fluticasone propionate/salmeterol xinafoate combination (Drug)
Phase: N/A
Status: Completed
Sponsored by: GlaxoSmithKline Official(s) and/or principal investigator(s): GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline
Summary
This is an observational retrospective analysis of linked pharmacy and medical claims data
from IMS Health/Pharmetrics database. which is a comprehensive, de-identified United States
(US) healthcare claims database that is representative of the non-elderly,
insurance-carrying population, The total population is 35. 4 million. The average length of
follow-up is 2. 7 years mean (2. 2 years median).
Subjects will be identified in the database that have at least one ICD-9 diagnostic code
(493. xx) for asthma and at least 1 asthma treatment within a 12-month period prior to the
index use of fluticsasone propionate/salmeterol xinafoate or inhaled corticosteroids.
Subjects will be followed in the database until they have the event of interest
(asthma-related emergency department visit, hospitalization, or oral corticosteroid use or
combination of asthma-related emergency department/hospitalization or asthma-related
emergency department/hospitalization/oral corticosteroids) or until they are lost to follow
up whichever comes first. Subjects can be censored if they leave the database, have the
event of interest, or are dispensed another asthma controller other than the medication of
interest. All outcomes will be assessed in the follow-up period. Time-dependent
statistical models adjusting for differences in baseline (pre-index) asthma and patient
demographics will be used to compare asthma events.
Clinical Details
Official title: Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients
Study design: Observational Model: Cohort, Time Perspective: Retrospective
Primary outcome: Asthma-related exacerbations
Eligibility
Minimum age: 12 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- One or more medical claims with a diagnosis (primary or secondary) of asthma
(ICD-9-CM 493. XX) during study period;
- One or more outpatient pharmacy claims during the study for one or more of the
following "study medications":
- Fluticasone propionate/salmeterol xinafoate 250 mcg/50 mcg or 100mcg/50mcg
combinations
- Fluticasone propionate 110 mcg or 220 mcg
- One or more asthma exacerbations (asthma-related hospitalization or emergency
department visit, oral corticosteriod prescription drug claim, or a combination of
any of the above events) during the 12 months prior to the index date ("pre-index
period") or
- Five or more prescriptions for a short-acting beta agonist during the pre-index
period.
Exclusion Criteria:
- Patients with more than one of the study medications during the 3-month period
beginning with the index date;
- One or more prescriptions within three months of index date (pre or post) for an ICS
or LABA other than the study medications
- One or more prescriptions within three months of post index date for:
- Any asthma maintenance medication
- Any medical claims during study period with a diagnosis of: Chronic obstructive
pulmonary disease (COPD) (ICD-9-CM 491, 492, or 496); or Respiratory tract cancer
(ICD-9-CM 160-164, or 231)
Locations and Contacts
Additional Information
Starting date: October 2010
Last updated: February 21, 2013
|